Targeting Oncogenic Gene Fusions in Lung Cancer

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Oncogenic gene fusions are key drivers in a subset of non-small cell lung cancer (NSCLC).
• Targeted therapies, including tyrosine kinase inhibitors and monoclonal antibodies, have significantly improved patient outcomes over the last 15 years.
• These advances include better response rates, progression-free survival, and central nervous system control.

Purpose of the Study:

• To review current evidence for FDA-approved therapies targeting specific gene fusions in lung cancer.
• To highlight mechanisms of action, clinical trials, resistance patterns, and toxicities of these targeted therapies.
• To discuss advances in molecular diagnostics and future strategies for fusion-driven NSCLC.

Main Methods:

• Literature review of pivotal clinical trials and FDA-approved therapies.
• Consolidation of evidence on mechanisms of action, resistance, and toxicity.
• Discussion of molecular diagnostic advances, including RNA-based sequencing.

Main Results:

• FDA-approved therapies targeting ALK, ROS1, RET, NTRK, and NRG1 fusions show substantial clinical benefits in NSCLC.
• Understanding resistance patterns and toxicity profiles is crucial for optimizing treatment.
• RNA-based sequencing is increasingly important for molecular diagnostics.

Conclusions:

• Targeted therapies have revolutionized the treatment of fusion-driven NSCLC.
• Ongoing research focuses on overcoming resistance and expanding precision oncology for rare fusion-driven lung cancers.
• Advances in diagnostics and treatment strategies are critical for improving patient care.